Consensus Conference on the DGVS on Gastroesophageal reflux. Subject group VI: Barrett's esophagus;Gastroösophageale Refluxkrankheit - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankhelten: Themenkomplex VI: Barrett-Ösophagus

Zeitschrift fur Gastroenterologie

Volumn 43, Issue 2, 2005, Pages 184-190

  Messmann, H ^a   Ell, C ^a   Fein, M ^a   Kiesslich, R ^a   Ortner, M ^a   Porschen, R ^a   Stolte, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; BARRETT ESOPHAGUS; CONFERENCE PAPER; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPY; HUMAN; INTESTINE METAPLASIA; RISK FACTOR; BIOPSY; CELL TRANSFORMATION; CONSENSUS DEVELOPMENT; ESOPHAGUS; ESOPHAGUS TUMOR; GASTROSCOPY; METAPLASIA; PATHOLOGY; PRECANCER;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; ENDOSONOGRAPHY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GASTROSCOPY; HUMANS; METAPLASIA; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 14744291617     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-857876     Document Type: Conference Paper

References (97)

1. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998; 93: 1028-1032
2. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus - the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998; 93: 1033-1036
3. Eloubeidi MA, Provenzeale D. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol 1999; 94: 937-943
4. Glickman JN, Wang H, Das KM et al. Phenotype of Barrett's esophagus and intetinal metaplasia of distal esophagus and gastroesophageal junction. Am J Surg Pathol 2001; 25: 87-94
5. McClave SA, Boyce HW Jr, Gottfried MR. Early diagnosis of columnar-lined esophagus: a new endoscopic diagnostic criterion. Gastrointest Endosc 1987; 33: 413-416
6. de Mas CR, Kramer M, Seifert E et al. Short Barrett: prevalence and risk factors. Scand J Gastroenterol 1999; 34: 1065-1070
7. Eisen GM, Sandler RS, Murray S et al. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997; 92: 27-31
8. Freston JW, Malagelada JR, Petersen H et al. Critical issues in the management of gastroesophageal reflux disease. Eur J Gasteroenterol Hepatol 1995; 7: 577-586
9. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997; 92: 1293-1297
10. Canto MI. Staining in gastrointestinal endoscopy: the basics. Endoscopy 1999; 31: 479-486
11. Weinstein WM, Ippoliti AF. The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc 1996; 44: 91-95
12. Alikhan M, Rex D, Khan A et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 1999; 50: 23-26
13. Reid BJ, Haggitt RC, Rubin CE et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988; 19: 166-178
14. Skacel M, Petras RE, Gramlich TL et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000; 95: 3383-3387
15. Wo JM, Ray MB, Mayfield-Stokes S et al. Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus: A preliminary study. Gastrointest Endosc 2001; 54: 294-301
16. Sharma P, Topalovski M, Mayo MS et al. Methylene blue chromoendoscopy for detection of short-segment Barrett's esophagus. Gastrointest Endosc 2001; 54: 289-293
17. Canto MI, Setrakian S, Willis J et al. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gastrointest Endosc 2000; 51: 560-568
18. Canto MI, Setrakian S, Petras RE et al. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 1996; 44: 1-7
19. Kiesslich R, Hahn M, Herrmann G et al. Screening for specialized columnar epithelium with methylene blue: chromoendoscopy in patients with Barrett's esophagus and a normal control group. Gastrointest Endosc 2001; 53: 47-52
20. Dave U, Shousha S, Westaby D. Methylene blue staining: is it really useful in Barrett's esophagus? Gastrointest Endosc 2001; 53: 333-335
21. Hackelsberger A, Günther T, Schultze V et al. Intestinal metaplasia at the gastro-oesophageal junction: Helicobacter pylori gastritis or gastro-oesophageal reflux disease? Gut 1998; 43: 17-21
22. Morales TG, Bhattacharyya A, Johnson C et al. Is Barrett's esophagus associated with intestinal metaplasia of the gastric cardia? Am J Gastroenterol 1997; 92: 1818-1822
23. Voutilainen M, Farkkila M, Juhola M et al. Complete and incomplete intestinal metaplasia at the oesophagogastric junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis. Gut 1999; 45: 644-648
24. Voutilainen M, Farkkila M, Juhola M et al. The Central Finland Endoscopy Study Group. Specialized columnar epithelium of the esophagogastric junction: prevalence and associations. Am J Gastroenterol 1999; 94: 913-918
25. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 1998; 12: 735-740
26. Stolte M, Meining A, Schmitz JM et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 247-253
27. Levine DS, Haggitt RC, Blount PL et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105: 40-50
28. Reid BJ, Blount PL, Feng Z et al. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95: 3089-3096
29. Alexander JA, Jones SM, Smith CJ et al. Usefulness of cytopathology and histology in the evaluation of Barrett's esophagus in a community hospital. Gastrointest Endosc 1997; 46: 318-320
30. Falk GW, Chittajallu R, Goldblum JR et al. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology 1997; 112: 1787-1797
31. Endlicher E, Knuechel R, Hauser T et al. Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitisation. Gut 2001; 48: 314-319
32. Reid BJ, Levine DS, Longton G et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000; 95: 1669-1676
33. Teodori L, Gohde W, Persiani M et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998; 34: 257-263
34. Falk GW, Catalano MF, Sivak MV Jr et al. Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia. Gastrointest Endosc 1994; 40: 207-212
35. May A, Gunter E, Roth F et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004; 53: 634-40
36. Messmann H, Schlottmann K. Role of endoscopy in the staging of esophageal and gastric cancer. Semin Surg Oncol 2001; 20: 78-81
37. Weston AP, Badr AS, Ruth S et al. Prospective multivariate analysis of clinical, endoscopic, and histologicaal factors predicitve of development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999; 94: 3413-3419
38. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998; 93: 1028-1032
39. Van der Burgh A, Dees J, Hop WC et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5-8
40. Iftikhar SY, James PD, Steele RJ et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 1155-1158
41. Menke-Pluymers MB, Hop WC, Dees J et al. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993; 72: 1155-1158
42. Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc 2000; 52: 328-332
43. Buttar NS, Wang KK, Sebo TJ et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120: 1630-1639
44. Faller G, Berndt R, Borchard F et al. Working Group for Gastroenterological Pathology, German Society for Pathology. Histopathological diagnosis of Barrett's mucosa and associated neoplasias. Results of a consensus conference of the Working Group for "Gastroenterological Pathology of the German Society for Pathology". Pathologe 2003; 24: 9-14
45. Gimenez A, Minguela A, Parrilla P et al. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus. Cancer 1998; 83: 641-651
46. Kim R, Clarke MR, Melhem MF et al. Expression of p53, PCNA, an C-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 1997; 42: 2463-2462
47. Weston AP, Banerjee SK, Sharma P et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001; 96: 1355-1362
48. Van Sandick JW, van Lanschot JJ, Kuiken BW et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43: 216-222
49. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105: 383-387
50. Fitzgerald RC, Saeed IT, Khoo D et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001; 46: 1892-1898
51. Wright TA, Gray MR, Morris AI et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996; 39: 574-579
52. Corley DA, Levin TR, Habel LA et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122: 633-640
53. Streitz J, Ellis F, Tilden R et al. Endoscopic surveillance of Barrett's esophagus: a cost-effectivness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998; 93: 911-915
54. Soni A, Sampliner R, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost effective? Am J Gastroenterol 2000; 95: 2086-2093
55. Eckhardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001; 111: 33-37
56. O'Connor J, Falk G, Richter J. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94: 2037-2042
57. Shaheen N, Crosby M, Bozymski E et al. Is there a publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-338
58. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002; 122: 588-590
59. Provenzale D, Schmitt C, Wong J. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043-2053
60. Sampliner RE. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-1895
61. Weston A, Krmpotich P, Cherian R et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: Comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol 1997; 92: 407-413
62. Wright TA. High-grade dysplasia in Barrett's oesophagus. Br J Surg 1997; 84: 760-766
63. Weston AP, Sharma P, Topalovski M et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95: 1888-1893
64. Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607-1619
65. Falk GW, Rice TW, Goldblum JR et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999; 49: 170-176
66. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-335
67. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-585
68. Wilkinson SP, Biddlestone L, Gore S et al. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily, results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999; 13: 1205-1209
69. Gore S, Healey CJ, Sutton R et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623-628
70. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995; 9: 451-454
71. Peters FT, Ganesh S, Kuipers EJ et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45: 489-494
72. Cooper BT, Neumann CS, Cox MA et al. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12: 893-897
73. Sagar PM, Ackroyd R, Hosie KB et al. Regression and progression of Barrett's oesophagus after antireflux surgery. Br J Surg 1995; 82: 806-810
74. McDonald ML, Trastek VF, Allen MS et al. Barrett's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996; 111: 1135-1138
75. Wang KK. Photodynamic therapy of Barrett's esophagus. Gastrointest Endosc Clin N Am 2000; 10: 409-419
76. Van Laethem JL, Cremer M, Peny MO et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-751
77. Pereira-Lima JC, Busnello JV, Saul C et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol 2000; 95: 1661-1668
78. Luman W, Lessels AM, Palmer KR. Failure of Nd-YAG photocoagulation therapy as treatment for Barrett's oesophagus - a pilot study. Eur J Gastroenterol Hepatol 1996; 8: 627-630
79. Wang KK, Sampliner RE. Mucosal ablation therapy of barrett esophagus. Mayo Clin Proc 2001; 76: 433-437
80. Gossner L, May A, Stolte M et al. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endosc 1999; 49: 8-12
81. Schulz H, Miehlke S, Antos D et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc 2000; 51: 659-663
82. Pelligrinin CA, Pohl D. High grade dyplasia in Barrett's esophagus: surveillance or operation? J Gastrointest Surg 2000; 4: 131-134
83. Birkmeyer JD, Siewers AE, Finlayson EV et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137
84. Barr H, Shepherd NA, Dix A et al. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996; 348: 584-585
85. Gossner L, Stolte M, Sroka R et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998; 114: 448-455
86. Ackroyd R, Brown NJ, Davis MF et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 2000; 47: 612-617
87. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49: 1-7
88. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58: 183-188
89. Overholt BF, Lightdale C, Wang C et al. International, multicenter, partially blinded randomised study of the efficacy of PDT using porfirmersodium (POR) for the ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE): Results of 24-month follow-up. Gastroenterology 2003; 124 (Suppl): 151
90. Ell C, May A, Gossner L et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118: 670-677
91. May A, Gossner L, Pech O et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002; 1410: 1085
92. Van Laethem JL, Jagodzinski R, Peny MO et al. Argon plasma coagulation in the treatment of Barrett's high-grade dysplasia and in situ adenocarcinoma. Endoscopy 2001; 33: 257-261
93. Pacifico RJ, Wang KK, Wongkeesong LM et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 2003; 1: 252-257
94. Stein HJ, Feith M, Mueller J et al. Limited resection for early adenocar-cinoma in Barrett's esophagus. Ann Surg 2000; 232: 733-742
95. Banki F, Mason RJ, DeMeester SR et al. Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg 2002; 236: 324-335
96. Ell C, May A, Gossner L et al. Kurative endoskopische Therapie früher Adenokarzinome der Speiseröhre. Deutsches Ärzteblatt 2003; 21: A1438-1448
97. Sibille A, Lambert R, Souquet JC et al. Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 1995; 108: 337-344